Sensei Biotherapeutics’ Future Hinges on Upcoming Clinical Data Release
Published on 09/24/2025 at 18:00 | Redaktion boerse-global.de
Clinical-stage biotech firm Sensei Biotherapeutics has scheduled a pivotal virtual event for October 20, 2025, where key opinion leaders will examine comprehensive data for its lead drug candidate, Solnerstotug. The full dose-expansion dataset, which is central to evaluating the therapy’s efficacy and safety profile in treating PD-(L)1-resistant tumors, will be presented just days prior at the European Society for Medical Oncology congress on October 17, 2025.
Solnerstotug is designed as a conditionally active antibody that specifically targets the VISTA checkpoint within the tumor microenvironment, with the goal of reactivating the immune system’s ability to fight cancer. Initial results from the Phase 1/2 study have already demonstrated encouraging activity. In evaluable patients with PD-(L)1-resistant “hot” tumors, an overall response rate of 14% was observed. This figure is nearly triple... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
